Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +27.42%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.52%
#5 Zilliqa Zilliqa +15.74%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Pharos Pharos +14.68%
#9 Taiko Taiko +14.38%
#10 Cap Cap +13.75%
Coin of the day
Orochi Network Orochi Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Kedudukan dalam Saham #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Harga Saham
$50.95
Modal Pasaran
$226.41B
Perubahan (1 hari)
2.58%
Perubahan (1 tahun)
-26.16%
Negara
DK
Perdagangan Novo Nordisk A/S (NVO)

Kategori

Healthcare
Hasil untuk Novo Nordisk A/S (NVO)
Hasil pada Mar 2026 TTM: $52.05B
Menurut laporan kewangan terkini daripada Novo Nordisk A/S, hasil semasa syarikat (TTM) ialah $52.05B. Pada tahun 2024, syarikat memperoleh hasil sebanyak $40.52B peningkatan berbanding hasil pada tahun 2023 iaitu $34.39B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Novo Nordisk A/S dari 2000 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $52.05B 11.49%
2025 $46.68B 15.22%
2024 $40.52B 17.82%
2023 $34.39B 35.02%
2022 $25.47B 18.29%
2021 $21.53B 3.33%
2020 $20.84B 13.79%
2019 $18.31B 6.63%
2018 $17.17B -4.59%
2017 $18.00B 13.46%
2016 $15.86B 0.88%
2015 $15.73B 8.89%
2014 $14.44B -6.28%
2013 $15.41B 11.69%
2012 $13.80B 19.42%
2011 $11.55B 6.01%
2010 $10.90B 10.52%
2009 $9.86B 15.53%
2008 $8.54B 3.65%
2007 $8.24B 20.44%
2006 $6.84B 28.15%
2005 $5.34B -0.14%
2004 $5.34B 18.51%
2003 $4.51B 27.01%
2002 $3.55B 25.45%
2001 $2.83B 9.05%
2000 $2.60B 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B -76.45%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B -71.33%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -82.55%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $4.94B -90.50%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
 $4.29B -91.76%
US